Delivery Order SPE2DB24D3013-SPE2DB25FFMNY

Award Date 6/16/25
Potential Completion Date 6/17/25
Potential Value $1.4K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This firm fixed price delivery order was awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a subsidiary of the global pharmaceutical distributor Amerisourcebergen Corporation. The $47,359.72 contract is for the supply of RESTASIS 0.05% eye emulsion to support military treatment programs and facilities. This order does not fall under any set-aside designation. Amerisourcebergen Drug Corp holds an Indefinite Delivery Contract (IDC) with DLA with...
This federal contract award was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,436.88 firm fixed-price delivery order is for RESTASIS 0.05% eye emulsion 30-count packages, with a completion date of December 4, 2024. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive range...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of RESTASIS 0.05% eye emulsion. The $34,149.58 firm-fixed-price contract has a completion date of May 24, 2024. No set-aside designation was used. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive range of...
The U.S. Defense Logistics Agency (DLA) awarded a Delivery Order contract worth $1,262.57 to Amerisourcebergen Drug Corp's Corporate Office Division. The contract is for the delivery of RESTASIS 0.05% Eye Emulsion, a prescription pharmaceutical product, with a performance period ending on April 24, 2024. This Delivery Order contract is part of Amerisourcebergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, which has a ceiling value of up to $999,999,999.00 and...
The Defense Logistics Agency (DLA) awarded a $2,384.16 delivery order contract to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of RESTASIS 0.05% eye emulsion. This delivery order is part of a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999.00 that Amerisourcebergen's parent company, Cencora, Inc., holds with the DLA Troop Support Medical. The IDC serves as a primary vehicle for Amerisourcebergen to provide a comprehensive range of...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of RESTASIS 0.05% eye emulsion. The $8,478.17 firm fixed-price contract has an ultimate completion date of July 20, 2022. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $53,146.20 fixed-price contract is for the delivery of RESTASIS 0.05% eye emulsion, a prescription eye medication, to support military healthcare programs. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as the primary vehicle for providing a...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The $20,634.64 contract is for the supply of RESTASIS 0.05% eye emulsion, a prescription medication. This delivery order is part of a larger $999,999,999.00 Indefinite Delivery Contract (IDC) held by AmerisourceBergen with DLA Troop Support Medical, which provides global pharmaceutical support to military healthcare programs through...
The Defense Logistics Agency (DLA) awarded a $1,080.48 firm-fixed-price delivery order contract to Amerisourcebergen Drug Corp's Corporate Office Division, a large pharmaceutical distribution company. The contract is for the supply of RESTASIS 0.05% eye emulsion, a prescription medication. This order is part of Amerisourcebergen's Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at up to $999,999,999.00 through December 2025. Under this single-award IDC,...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The $3,569.36 firm fixed-price contract is for the supply of RESTASIS 0.05% eye emulsion. It is a non-set-aside award with a completion date of August 8, 2024. Amerisourcebergen holds a larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at up to $999,999,999 through December 2025, for providing a comprehensive range of medical...
  • SPE2DB24D3013
    Indefinite Delivery Contract
  • SPE2DB24D3013-SPE2DB25FFMNY
    Delivery Order

This is a $1,359.21 firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of RESTASIS 0.05% eye emulsion and does not have a set-aside designation, indicating open competition. AmerisourceBergen Drug Corp holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, which provides a comprehensive global pharmaceutical support vehicle with a performance period extending through December 2026. This IDC enables the company to supply a wide range of pharmaceutical products and medical supplies to support military healthcare programs worldwide, serving customers including the Defense Health Agency and U.S. Coast Guard.

Generated 9/15/25, 9:52 AM